title: Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome.
abstract: OBJECTIVE
  To determine the effects of metformin treatment on serum androgen levels ahead of and during the IVF cycle in infertile polycystic ovary syndrome (PCOS) women.
  
  
  METHODS
  A prospective, double-blind, placebo-controlled study.
  
  
  METHODS
  Single-center, university IVF clinic.
  
  
  METHODS
  Sixty-three PCOS women.
  
  
  METHODS
  Treatment with metformin 2,000 mg/day or identical placebo tablets for at least 14 weeks before and then during IVF treatment, ending on the day of hCG injection.
  
  
  METHODS
  Serum levels of dehydroepiandrosterone, dehydroepiandrosterone sulphate (DHEAS), androstenedione, free testosterone index (FTI), dihydrotestosterone, and the androgen metabolite 5alpha-androstane-3alpha, 17beta-diol-glucuronide were measured at five time points ending on the day of ovum collection.
  
  
  RESULTS
  During metformin pretreatment DHEAS increased, wheres other androgens were unaffected. During the IVF procedure androgens were unaffected by metformin treatment. Within 36 hours after the study medication was withdrawn the levels of androstenedione and FTI increased in the metformin group, whereas DHEAS decreased.
  
  
  CONCLUSIONS
  In infertile PCOS women metformin treatment increased DHEAS levels. During the IVF cycle androgen levels were unaffected by metformin, whereas there was a "rebound" effect when stopping metformin treatment.
authors.affiliation: Department of Obstetrics and Gynaecology, St. Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway. sigrun.kjotrod@stolav.no
authors.forename: Sigrun B
authors.initials: SB
authors.lastname: Kjøtrød
authors.forename: Arne
authors.initials: A
authors.lastname: Sunde
authors.forename: Vidar
authors.initials: V
authors.lastname: von Düring
authors.forename: Sven M
authors.initials: SM
authors.lastname: Carlsen
mesh_terms: D000311:Adrenal Glands / Q000187:drug effects* / Q000378:metabolism; D000328:Adult; D000728:Androgens / Q000097:blood*; D015992:Body Mass Index; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005307:Fertilization in Vitro; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008687:Metformin / Q000627:therapeutic use*; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000728:Androgens; D006063:Chorionic Gonadotropin; D005300:Fertility Agents, Female; D007328:Insulin; D019314:Dehydroepiandrosterone Sulfate; D008687:Metformin